Scientists have developed a new drug delivery platform that can pass through the blood-brain barrier

The blood-brain barrier is a special vascular system that provides nutrients in the blood to the brain, as well as a semi-permeable membrane barrier that protects the brain from pathogens, bacteria, etc.
this barrier can also cause drugs to fail to effectively enter the brain through the blood-brain barrier, which can affect treatment efficiency.
recently, research teams at Brigham and Women's Hospital in Boston and Boston Children's Hospital developed a nanomoleam transport platform that promotes the effective delivery of drugs through the blood-brain barrier to the brains of mice.
the study, published in the journal Science Advances, was published in the journal BBB pathophysio-independent delivery of siRNA in the brain injury.
polylactic acid-hydroxyacetic acid (PLGA) is a biodegradable biocompasitive polymer that is the basis of nano-molecular materials.
the drug used by the researchers is a small interfering RNA molecule (siRNA) that inhibits the expression of the tau protein, which is thought to play a key role in neurodegenerative changes.
researchers used PLGA to develop a nanoscale surface protein that combines the therapeutic drug siRNA to maximize penetration of the blood-brain barrier in laboratory mice.
study found a 50 percent reduction in tau protein expression in mice that absorbed siRNA through the new drug delivery platform compared to mice that absorbed siRNA through a conventional drug delivery platform, indicating a significant increase in the number of therapeutic drugs entering the brains of mice through the new drug delivery platform.
the results confirm that the new drug delivery platform can greatly improve the efficiency of the drug through the blood-brain barrier.
this study proves the practical value of this new nanoscale drug delivery platform and provides new ideas for the treatment of many neurological diseases in the future.
(）